Atilotrelvir (development code GST-HG171) is a drug for the treatment of COVID-19. It has broad-spectrum anti-SARS-CoV-2 activity against different variants (including WT, β, δ, and omicron).

In combination with ritonavir, it was approved for use in China in 2023.